Skip to main content

Table 2 Adverse events (worst grade; ≥ 2pts) possibly, probably or definitely related to the study regimen (N = 30)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Type

Any Grade

Grade 3

Grade 4

No. patients

%

No. Pts.

%

No. Pts.

%

Skin

 Pruritus

19

63

2

7

0

0

 Rash maculopapular

14

47

6

20

0

0

Gastrointestinal

 Diarrhea/Colitis

15

50

3

10

0

0

 Nausea

16

53

1

3

0

0

 Vomiting

9

30

1

3

0

0

Hepatic

 ALT

22

73

6

20

0

0

 AST

28

93

5

17

1

3

Endocrine

 Hypothyroidism

8

27

0

0

0

0

 Hyperthyroidism

3

10

0

0

0

0

 Adrenal insufficiency

10

33

3

10

0

0

 Hypophysitis

2

7

2

7

0

0

 Lipase increased

9

30

3

10

0

0

Hematologic

 Neutropenia

21

70

2

7

0

0

 Thrombocytopenia

20

67

0

0

0

0

Other

 Fever

17

57

0

0

0

0

 Fatigue

27

90

16

53

0

0

 CPK increased

19

63

2

7

0

0

 Creatinine increased

6

20

2

7

0

0